Changes of the diastolic function of left ventry in patients with arterial hypertension in the process of micardis treatment in the family doctor's conditions
DOI:
https://doi.org/10.34287/MMT.1(40).2019.7Abstract
Among 38 patients with arterial hypertension I and II degree, the diastolic function of the left ventricle was studied in the course of a twelve-month treatment with Telmisartan (Micardis). Analysis of the diastolic function of the left ventricle before the treatment with telmisartan showed that in both groups of patients with respect to the control group there was a significant decrease in the maximum speed of early diastolic filling and an increase in the maximum rate of atrial filling with increasing severity of the disease.
At the same time, the period of isovolumetric relaxation and the end diastolic pressure in the left ventricle increased, and the E/A and Ei/Ai ratios tended to decrease. At the end of the 12-month period of treatment with micardis, the achievement of target levels of blood pressure and normalization of diastolic function of the left ventricle were noted.
References
A global summary on hypertension. The silent killer, the global public health crisis]. WHO, 2013. WHO/DCO/WHD/2013.2, (in Russian).
Diachuk D. D. et al. The prevalence of risk factors for cardiovascular disease in Ukraine: a modern view of the problem. Ukrainskyi kardiolohichnyi zhurnal, 2018, № 1, pp. 99–101.
Ivanova O. V. The blocker of angiotensin II receptors telmisartan: the effect on the daily profile of arterial pressure and myocardial hypertrophy of the left ventricle among patients with arterial hypertension. Kardiologiya, 2012, № 2, pp. 45–49.
Kislyak O. A. The possibility of blockade of the renin-angiotensin-aldosterone system in patients with cardiovascular high risk]. Farmoteka, 2016, № 12, pp. 25–28.
Kovalenko V. M., Dorohoi A. P. Cardiovascular diseases: medical and social significance and strategy of cardiology development in Ukraine. Ukr. kardiolohichnyi zhurnal, 2016, addition 3, pp. 5–14.
Benson S. C. etal. Identificationof Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity. Hypertension, 2014, vol. 43, № 5, pp. 993–1002. DOI: 10.1161/01.HYP.0000123072.34629.57.
